Physician profile
Nirali Patel
NPI 1720115041
$1,311.50
in general payments reported to CMS, 2019-2025
19 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $67.28 · 2022: $13.26 · 2023: $300 · 2024: $435 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.42 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.95 | 2023-2025 | |
| Lilly USA, LLC | $199.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $131.07 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $130.81 | 2019-2024 | Arexvy, Shingrix |
| Currax Pharmaceuticals LLC | $101.85 | 2023-2025 | Contrave, Onzetra Xsail, Nexletol |
| Amgen INC. | $98.15 | 2024-2025 | Otezla, Repatha, Evenity |
| Ars Pharmaceuticals Operations, INC. | $96.20 | 2025 | Neffy |
| Exact Sciences Corporation | $67.75 | 2023-2024 | Cologuard Collection Kit |
| Ascensia Diabetes Care US INC. | $42.47 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $36.85 | 2019 | |
| Allergan, INC. | $27.86 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $23.11 | 2024 | |
| Echosens North America, INC. | $18.68 | 2025 | Fibroscan |
| Otsuka America Pharmaceutical, INC. | $17.58 | 2024 | Rexulti |
| Baxter Healthcare | $16.08 | 2025 | Biopharma Sol - Contract Manuf |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.35 | 2024 | Voquezna |
| Kaleo, INC. | $12.42 | 2020 | |
| Horizon Therapeutics Plc | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.